Takeda and Protagonist Therapeutics, Inc. Enter into Worldwide License and Collaboration Agreement for Rusfertide, a Late-Stage Rare Hematology Asset : vimarsana.com

Takeda and Protagonist Therapeutics, Inc. Enter into Worldwide License and Collaboration Agreement for Rusfertide, a Late-Stage Rare Hematology Asset

Takeda and Protagonist Therapeutics, Inc. Enter into Worldwide License and Collaboration Agreement for Rusfertide, a Late-Stage Rare Hematology Asset

streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Related Keywords

United States , Cambridge , Cambridgeshire , United Kingdom , Japan , Osaka , Japanese , American , Ann Hematol , Dineshv Patel , Corey Davis , Megan Ostrower , Jun Saito , Julie Kim , Takeda Pharmaceuticals United Statesa Inc , American Society Of Hematology , Exchange Commission , Takeda Pharmaceutical Company Limited , Us Co , Be Protagonist Co , Japan Ministry Of Health , International Media , European Medicines Agency , Nasdaq , Network Of Companies , Protagonist Therapeutics Inc , Drug Administration , Takeda Will Be Protagonist , Commercialization Partner With , With Exclusive Ex U , Commercialize Rusfertide , Polycythemia Vera , Will Make , Upfront Payment , Combines Protagonist , Commercial Expertise , Plus Year Legacy , Driving Innovation Within , Rare Hematology , Host Conference Call , Webcast Today , Protagonist Therapeutics , American Society , Orphan Drug Designation , Fast Track , Rare Pediatric Disease , Rare Pediatric Disease Voucher , Specific Populations , Takeda Pharmaceuticals United Statesa , Prescribing Information , Leuk Lymphoma , Englj Med , Media Contacts , Therapeutics Investor , Annual Report , Therapeutics Cautionary Note , Private Securities Litigation Reform Act ,